<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031668</url>
  </required_header>
  <id_info>
    <org_study_id>LY8</org_study_id>
    <secondary_id>CAN-NCIC-LY8</secondary_id>
    <secondary_id>CDR0000069214</secondary_id>
    <nct_id>NCT00031668</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation</brief_title>
  <official_title>A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet&#xD;
      known if giving radiation therapy after stem cell transplantation is more effective than stem&#xD;
      cell transplantation alone in treating relapsed or refractory non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of radiation therapy in&#xD;
      treating patients who have relapsed or refractory non-Hodgkin's lymphoma and have undergone&#xD;
      autologous stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the 3-year progression-free survival of patients with relapsed or refractory&#xD;
           aggressive non-Hodgkin's lymphoma treated with high-dose chemotherapy and autologous&#xD;
           hematopoietic stem cell transplantation with or without involved-field radiotherapy.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare 3-year progression-free disease within and outside radiotherapy fields in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      response to pre-salvage chemotherapy (primary refractory disease vs relapse), response to&#xD;
      post-salvage chemotherapy (complete/unconfirmed complete vs partial), and participating&#xD;
      center. Within 6-8 weeks after completion of autologous hematopoietic stem cell&#xD;
      transplantation, patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo involved-field radiotherapy (IFRT) 5 days a week for 3-5 weeks&#xD;
           in the absence of unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients undergo observation only. Quality of life in arm I is assessed at&#xD;
           baseline, on day 1 of IFRT, at weeks 2 and 4 during IFRT, at 1 month, 4 months, every 3&#xD;
           months for 2 years, every 6 months for 1 year, and then annually for 2 years. Quality of&#xD;
           life in arm II is assessed at baseline, 1 month, 2 months, every 3 months for 2 years,&#xD;
           every 6 months for 1 year, and then annually for 2 years.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 2 years, every 6 months for 1 year, and&#xD;
      then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 230 patients (115 per treatment arm) will be accrued for this&#xD;
      study within 4.2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2001</start_date>
  <completion_date type="Actual">February 10, 2009</completion_date>
  <primary_completion_date type="Actual">February 10, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">6</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma&#xD;
                  and T-cell rich B-cell lymphoma)&#xD;
&#xD;
               -  Previous indolent lymphoma (follicular center cell lymphoma, marginal zone&#xD;
                  lymphoma, including extranodal MALT lymphoma and lymphoplasmacytoid lymphoma)&#xD;
                  with transformation to diffuse large B-cell lymphoma at relapse&#xD;
&#xD;
               -  Peripheral T-cell lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma (T cell or null cell)&#xD;
&#xD;
               -  Small non-cleaved Burkitt-like lymphoma&#xD;
&#xD;
          -  Relapsed or refractory disease after first-line anthracycline-based chemotherapy&#xD;
&#xD;
               -  Bulky disease, nodal or extranodal&#xD;
&#xD;
                    -  Clinically or radiographically measurable mass at least 5 cm in diameter OR&#xD;
&#xD;
               -  Non-bulky disease, nodal or extranodal, excluding diffuse organ (lung, liver,&#xD;
                  kidney, or bone marrow) involvement&#xD;
&#xD;
                    -  Clinically or radiographically measurable disease more than 1.5 cm in&#xD;
                       greatest transverse diameter&#xD;
&#xD;
          -  Biopsy at relapse not required except for transformed lymphomas&#xD;
&#xD;
               -  Patients with transformed lymphoma at diagnosis, but with indolent histology&#xD;
                  without transformation at relapse, are not eligible&#xD;
&#xD;
          -  No patients with stage IA or IIA disease at initial diagnosis who, at time of relapse&#xD;
             or diagnosis of refractory disease prior to salvage therapy, remained in stage IA or&#xD;
             IIA, with no new disease sites, without having received radiotherapy&#xD;
&#xD;
          -  Received up to 2 regimens and 4 courses of salvage chemotherapy&#xD;
&#xD;
               -  Monoclonal antibodies (e.g., rituximab) are not considered salvage chemotherapy&#xD;
&#xD;
               -  Achieved complete response (CR), unconfirmed CR, or partial response (PR) if&#xD;
                  bulky disease OR&#xD;
&#xD;
               -  Achieved PR (but not CR) if non-bulky disease&#xD;
&#xD;
          -  No residual disease involving extranodal organs diffusely (e.g., liver, lung, bone,&#xD;
             kidney, or leptomeningeal) after salvage chemotherapy&#xD;
&#xD;
          -  Planned autologous hematopoietic stem cell transplantation (ASCT)&#xD;
&#xD;
               -  ASCT conditioning must be with high-dose BEAM (carmustine, etoposide, cytarabine,&#xD;
                  and melphalan) chemotherapy&#xD;
&#xD;
          -  No disease progression after ASCT&#xD;
&#xD;
          -  No major organ complication or poor hematologic recovery from ASCT that would preclude&#xD;
             initiation of study radiotherapy within 14 weeks after ASCT&#xD;
&#xD;
          -  No more than 2 non-contiguous nodal or extranodal areas of bulky/residual disease&#xD;
             requiring more than 2 separate involved-field radiotherapy volume arrangements (e.g.,&#xD;
             field arrangement covering up to 2 involved lymph node regions or extranodal sites,&#xD;
             with or without 1 adjacent nodal/region or extranodal site)&#xD;
&#xD;
          -  No active CNS lymphoma (parenchymal brain and/or leptomeningeal)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell carcinoma of the skin&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior total body irradiation&#xD;
&#xD;
          -  No prior radiotherapy to the site of bulky disease or residual tumor&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anti-cancer therapy unless documentation of disease progression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Tsang, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newfoundland Cancer Treatment and Research Foundation</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>June 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2003</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

